Investors
Phase II company positioned for growth
Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and pulmonary rare disease market with an innovative pipeline of clinical and preclinical drug candidates. The strategic focus on rare disease with our clinical portfolio not only benefits underserved patients, but also provides a compelling business model characterized by relatively shorter development timelines, reduced capital requirements and the potential for accelerated market entry.
Pipeline
Innovative pipeline offering disease-modifying drug candidates
We are advancing an innovative pipeline that includes an HDACi portfolio with two drug candidates in clinical phase, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. In preclinical stage, our drug candidate CS585, a novel prostacyclin (IP) receptor agonist, has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease.
Therapeutic focus
Strengthened focus on rare disease
At Cereno, we have the potential to deliver high treatment value to patients leveraging our innovative pipeline and disease-modifying approach to address the root mechanism of rare and fatal diseases. We are committed to pioneering treatments to enhance and extend life for people suffering from rare cardiovascular and pulmonary diseases, who today have unmet medical needs.